Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

HB 2695Session 2025-2026

Enacting the enhanced oversight and accountability for the prescription of psychotropic drug prescriptions act to require the secretary of health and environment to establish an online reporting system for adverse drug reactions.

As Introduced

Skip to main content Kansas Legislature kslegislature.gov menu Home House account_balanceAbout the House groupsRepresentatives campaignEvents chairSeating Chart auto_storiesJournals & Calendars manage_accountsChief Clerk of the House gavelRules Senate account_balanceAbout the Senate groupsSenators campaignEvents assignment_indAppointments chairSeating Chart auto_storiesJournals & Calendars manage_accountsSecretary of the Senate gavelRules Committees groupsCommittees eventHearing Schedule handshakeConference Committee Schedule Measures & Laws gavelAll Measures account_balanceHouse Measures account_balanceSenate Measures account_balanceVotes topicSubject Index summarizeReports menu_bookStatutes schoolHow a Bill Becomes Law menu_bookLegislative Procedure Manual Today campaignLive Floor Activity videocamHouse Video videocamSenate Video live_tvStatehouse Live & Archive smart_displayYouTube Channel Resources Archive Search description Go to bill or resolution arrow_forward A− A+ search Search bills, resolutions, and statutes help

Keywords
Enter any words to search bills, statutes, and documents.
water quality funding

Bill or Resolution Number
Type a number and press Enter to go directly to the detail page.
HB 2590 SCR 1611

Statute Number
68-102 72-3715

Exact Phrase
Wrap your query in quotes.
“rules of evidence”

Document Type
Prefix with a type to narrow results.
testimony: HB 2513 minutes: budget

    Searching…

    No results found.

    search Search bills, resolutions, and statutes Home House About the House Representatives Events Seating Chart Journals & Calendars Chief Clerk of the House Rules Senate About the Senate Senators Events Appointments Seating Chart Journals & Calendars Secretary of the Senate Rules Committees All Committees Hearing Schedule Conference Committee Schedule Measures & Laws All Measures House Measures Senate Measures Votes Subject Index Reports Statutes How a Bill Becomes Law Legislative Procedure Manual Resources Today Live Floor Activity House Video Senate Video Statehouse Live & Archive YouTube Channel Archive Search
    1. HB 2695›
    2. HB 2695 — As Introduced

    Kansas Legislature

    HB 2695 — As Introduced

    picture_as_pdf Download PDF Session of 2026HOUSE BILL No. 2695By Representative Howe2-41AN ACT concerning health and healthcare; relating to children receiving 2medical assistance; enacting the enhanced oversight and accountability 3for the prescription of psychotropic drug act; enhancing oversight of 4psychotropic drug prescriptions for children receiving medical 5assistance; requiring the department of health and environment to 6establish an adverse drug reaction online reporting system.78WHEREAS, In 2023, KanCare statistics showed that 37,372 children 9and adolescents from ages 0-17 were prescribed psychotropic drugs, 10including 2,784 aged 0-5; and11WHEREAS, The administration of most psychotropic drugs to children 12aged 0-5 is prescribed off-label, meaning that the drugs are being 13prescribed for an age group that is not approved by the United States food 14and drug administration (FDA); and15WHEREAS, Psychotropic drugs, including stimulants, antidepressants, 16antipsychotics and other behavioral drugs, are being prescribed to children 17receiving medical assistance and are documented by the FDA to include 18severe side effects, including but not limited to, addiction, suicidal 19ideation, aggression, hallucinations, cardiovascular events, stunted growth 20and developmental concerns; and21WHEREAS, Parents and caregivers are frequently not informed of the 22risks posed by the off-label prescription of psychotropic drugs documented 23by the FDA, including the pediatric risks; and24WHEREAS, 21 C.F.R. § 208.20 establishes a requirement for FDA 25medication guides to provide nontechnical, understandable information 26about the potential risks and side effects of prescription drugs to the 27average consumer, including parents and caregivers. According to 21 28C.F.R. § 208.20, medication guides must detail the particular and 29significant public health concern that created the need for a medication 30guide, note any pediatric risks, include the risk of patients developing a 31dependence on the drug, use a font no smaller than 10-point and not be 32promotional in tone or content; and33WHEREAS, To effectively monitor the effects of psychotropic drugs 34prescribed to children and adolescents, particularly those drugs cited by 35the FDA for having pediatric risks, parents and caregivers must be given a 36hard copy of the FDA medication guide for the psychotropic drug 1prescribed; and2WHEREAS, The state's medical assistance program is a state and 3federally funded program that provides essential healthcare services to 4vulnerable populations, including children and adolescents. It should be 5required to distribute the FDA medication guides to ensure patients and 6their guardians are fully informed of the risks and potential side effects of 7psychotropic drugs, thereby supporting informed consent and promoting 8patient safety; and9WHEREAS, A reliable system for parents and caregivers to report 10adverse drug reactions to psychotropic drugs is essential to help state 11medical assistance program agencies and legislators monitor and assess the 12frequency, severity and impact of such reactions within the public sector; 13and14WHEREAS, The absence of an accessible reporting mechanism for 15psychotropic drug side effects funded by a medical assistance program 16limits the ability to identify and address these risks effectively, 17compromising the safety of children and adolescents; and18WHEREAS, The state's medical assistance program is the primary 19payer for psychotropic drugs prescribed to children and adolescents in the 20public sector, including for off-label use in children, making it directly 21responsible for ensuring the safety and monitoring of these prescriptions; 22and23WHEREAS, Adverse drug reactions to psychotropic drugs can have 24significant physical, psychological and developmental impacts on children, 25requiring timely identification and response to mitigate harm; and26WHEREAS, The establishment of an online adverse drug reactions 27reporting system would enable the state medical assistance program to 28fulfill its duty of care by providing a mechanism to collect critical safety 29data, support evidence-based decision making and comply with its 30responsibility to protect public health; and31WHEREAS, Funding this reporting system aligns with the state 32medical assistance program's obligations under federal law to monitor and 33improve the quality of care to its beneficiaries, especially vulnerable 34pediatric patients, and would facilitate oversight and accountability for the 35use of public funds in prescribing psychotropic drugs; and36WHEREAS, The Kansas legislature establishes the following 37provisions to enhance oversight, informed consent and accountability for 38the prescription of psychotropic drugs to children receiving medical 39assistance.40Now, therefore:41Be it enacted by the Legislature of the State of Kansas:42Section 1. Sections 1 through 6, and amendments thereto, shall be 43known and may be cited as the enhanced oversight and accountability for 1the prescription of psychotropic drug act.2Sec. 2. As used in this act:3(a) "Adverse drug reaction" means any unintended harmful reaction 4of a psychotropic drug.5(b) "Child" means an individual under 18 years of age.6(c) "Medication guide" means a handout produced by the United 7States food and drug administration that accompanies certain prescription 8medications with significant safety concerns and are used to inform 9patients and caregivers about risks, side effects and proper usage.10(d) "Medical assistance" means the same as defined in K.S.A. 39-702, 11and amendments thereto.12(e) "Parent" includes a parent or guardian and every person who is by 13law liable to maintain, care for or support the child.14(f) "Prescriber" means the same as defined in K.S.A. 65-1626, and 15amendments thereto.16(g) "Psychotropic drugs" mean medications that affect the mind, 17emotions or behavior, including, but not limited to, stimulants, 18antidepressants, antipsychotics or other behavioral drugs authorized or 19funded under the state medical assistance program.20(h) "Online reporting system" means a web-based platform through 21which a child receiving medical assistance or such child's parent can report 22an adverse drug reaction related to psychotropic drug use.23Sec. 3. (a) Before prescribing or administering a psychotropic drug to 24a child receiving medical assistance, a prescriber shall provide any 25medication guide for such drug to such child's parent.26(b) Medication guides shall be provided to a parent in writing and 27reviewed with the parent to make them aware of:28(1) Potential side effects identified by the United States food and drug 29administration, as well as cautionary monitoring citations;30(2) any United States food and drug administration black box 31warning that details serious or life-threatening risks; and32(3) pediatric-specific side effects or warnings relating to children and 33adolescents.34(c) Before prescribing or administering a psychotropic drug, written 35informed consent shall be obtained from a parent. Such written informed 36consent shall be:37(1) Signed by a parent, confirming that they have received and 38reviewed the medication guide and understand the associated risks of the 39medication that is being prescribed; and40(2) kept on file by the prescriber, with a copy provided to the parent 41or legal guardian.42Sec. 4. (a) The secretary of health and environment shall develop and 43maintain a secure online reporting system for adverse drug reactions 1related to psychotropic drugs prescribed to children. The reporting system 2shall include, at minimum, the following fields:3(1) Name of the patient;4(2) age of the patient;5(3) class of the prescribed psychotropic drug;6(4) name of the prescribed psychotropic drug;7(5) type of adverse reaction, including, but not limited to:8(A) Physical reactions, such as gastrointestinal issues, neurological 9issues, cardiovascular symptoms, endocrine or metabolic effects or allergic 10reactions;11(B) physiological reactions, such as mood changes, increased anxiety, 12hallucinations or delusions, agitation or restlessness or suicidal thoughts; 13and14(C) behavioral reactions, such as sleep disturbances, increased 15aggression, mania, cognitive impairments, self-harm or disassociation;16(6) severity level of such reaction, to be measured as either mild, 17moderate or severe; and18(7) name of the person reporting the reaction, such person's relation 19to the patient and the phone number and email address of the person 20reporting the reaction.21(b) (1) Documents or other information reported or maintained by the 22secretary pursuant to subsection (a) shall be confidential and privileged 23and shall not be subject to disclosure under the open records act, K.S.A. 2445-215, et seq., and amendments thereto.25(2) The provisions of this subsection shall expire on July 1, 2031, 26unless the legislature reviews and reenacts this provision pursuant to 27K.S.A. 45-229, and amendments thereto, prior to July 1, 2031.28(c) On and after the first day of the legislative session of 2027, the 29secretary of health and environment shall compile and submit quarterly 30reports that summarize the adverse drug reaction data related to 31psychotropic drugs prescribed to children and adolescents and submit such 32reports to the senate standing committee on ways and means, the house of 33representatives standing committee on appropriations, the house of 34representatives standing committee on social services budget and the 35Robert G. Bethell joint committee on home and community-based services 36and KanCare oversight. Such reports shall include:37(1) The overall number of adverse drug reactions reported and 38categorized by age;39(2) the total number of adverse reactions categorized by severity 40level; and41(3) a breakdown of adverse drug reactions by adverse drug reaction 42category, detailing the number of incidents for each category.43(d) Any information submitted to committees shall be disaggregated 1by age, gender and race and shall not include any personally identifiable 2information. Such legislative committees shall review such reports and 3may recommend actions to improve the safety of prescribing psychotropic 4drugs.5(e) The secretary of health and environment shall allocate moneys to 6establish and maintain the adverse drug reaction online reporting system 7and may seek additional moneys as needed.8Sec. 5. On and after the first day of the legislative session of 2027, 9the secretary of health and environment shall submit annual reports to the 10senate standing committee on ways and means, the house of 11representatives standing committee on appropriations, the house of 12representatives standing committee on social services budget and the 13Robert G. Bethell joint committee on home and community-based services 14and KanCare oversight summarizing implementation efforts, compliance 15statistics and the impact of sections 1 through 4, and amendments thereto, 16including fiscal analysis and health outcomes.17Sec. 6. This act shall take effect and be in force from and after its 18publication in the statute book. search keyboard_arrow_up keyboard_arrow_down Page 1 Page 2 Page 3 Page 4 Page 5 arrow_upward Top Kansas State Legislature

    300 SW 10th Ave, Topeka, KS 66612

    Ad Astra Per Aspera

    Kansas Legislative Hotline
    In-State: 1-800-432-3924
    Out-of-State: 785-296-2149

    Government

    • Legislators
    • House
    • Representatives
    • Senate
    • Senators
    • Committees

    Resources

    • Bills & Measures
    • Today
    • Live
    • Journals
    • Calendars
    • Archived Records
    • Laws
    • Search
    • RSS Feeds

    Support

    • Contact Us
    • Accessibility
    • Privacy Policy
    • Visit Us
    © 2026 Kansas State Legislature. All rights reserved. Data updated 0 minutes ago · 1:12 AM 11/14/2026

    Official text from the Kansas Legislature. Formatting has been adapted for reading on Ratifi.